Technical Analysis for RCUS - Arcus Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 5.57% | |
| Gapped Down | Weakness | 5.57% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.78% | |
| Doji - Bearish? | Reversal | 0.78% | |
| Wide Bands | Range Expansion | 0.78% | |
| Wide Bands | Range Expansion | 0.32% | |
| Oversold Stochastic | Weakness | 0.32% | |
| Lower Bollinger Band Walk | Weakness | 5.93% | |
| Oversold Stochastic | Weakness | 5.93% |
| Alert | Time |
|---|---|
| Up 5% | about 15 hours ago |
| 60 Minute Opening Range Breakout | about 16 hours ago |
| Rose Above Previous Day's High | about 16 hours ago |
| Rose Above 10 DMA | about 16 hours ago |
| Outside Day | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.47 |
| 52 Week Low | 12.96 |
| Average Volume | 785,515 |
| 200-Day Moving Average | 17.52 |
| 50-Day Moving Average | 17.43 |
| 20-Day Moving Average | 16.29 |
| 10-Day Moving Average | 15.23 |
| Average True Range | 0.91 |
| RSI (14) | 44.13 |
| ADX | 18.48 |
| +DI | 17.31 |
| -DI | 21.88 |
| Chandelier Exit (Long, 3 ATRs) | 16.37 |
| Chandelier Exit (Short, 3 ATRs) | 16.84 |
| Upper Bollinger Bands | 18.67 |
| Lower Bollinger Band | 13.92 |
| Percent B (%b) | 0.34 |
| BandWidth | 29.13 |
| MACD Line | -0.68 |
| MACD Signal Line | -0.61 |
| MACD Histogram | -0.071 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.09 | ||||
| Resistance 3 (R3) | 16.94 | 16.28 | 16.83 | ||
| Resistance 2 (R2) | 16.28 | 15.89 | 16.35 | 16.75 | |
| Resistance 1 (R1) | 15.91 | 15.64 | 16.10 | 16.06 | 16.66 |
| Pivot Point | 15.25 | 15.25 | 15.34 | 15.33 | 15.25 |
| Support 1 (S1) | 14.89 | 14.86 | 15.07 | 15.04 | 14.44 |
| Support 2 (S2) | 14.23 | 14.62 | 14.30 | 14.35 | |
| Support 3 (S3) | 13.86 | 14.23 | 14.27 | ||
| Support 4 (S4) | 14.01 |
